Glaukos Corporation

Glaukos Corporation (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company that is focused on developing therapies for the treatment of glaucoma, corneal disorders, and retinal disease. The Company’s products are designed to treat mild-to-moderate open-angle glaucoma, the iStent, the iStent inject, and the iStent inject W. The Company’s Micro-Invasive Glaucoma Surgery (MIGS) serves as an alternative to the traditional glaucoma treatment paradigm. It offers bio-activated pharmaceutical therapy for the treatment of corneal disorder and keratoconus. It is also developing a pipeline of surgical devices, sustained pharmaceutical therapies, implantable biosensors intended to treat glaucoma progression, corneal disorders such as keratoconus, dry eye, refractive vision correction, retinal diseases such as neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion.

• Glaukos Corporation